We have uncovered new cellular mechanisms for adaptive immune responses mediated by glycoconjugate immunization. Following immunization, glycoconjugates undergo enzymatic and oxidative changes resulting in relatively small glycan-peptides being mounted onto MHCII, with the peptide serving as the MHCII anchor and the carbohydrate presented to and recognized by the CD4+T cell (Tcarb). Importantly, the peptide is not recognized by the Tcarb, only the glycan. Presentation of the carbohydrate is the key event required for very robust T cell help in order for the B cell to make very high-titered anti-glycan antibodies. Demystifying the Tcell activation mechanisms of glycoconjugate vaccines was a key step towards designing new-generation vaccines as outlined in this proposal. We learned from our mechanistic studies that the most important feature of an ideal glycoconjugate vaccine is enrichment for these glycan-peptide epitopes. We synthesized a prototype new-generation glycoconjugate vaccine and tested it for immunogenicity and protective capacity in comparison to a traditionally made glycoconjugate vaccine. Our results showed that the new-generation vaccine was 50-100x more immunogenic and protective than the traditional vaccine. In this proposal, we build on our mechanistic studies and develop a translational platform for optimizing carbohydrate-based vaccines to produce a new generation of vaccines applicable to many microbial glycans. There are two Specific Aims: 1) Optimization of the platform construct for glycoconjugate vaccines. In this Specific Aim, we will optimize the carrier peptide, the glycan chain length, and the glycoconjugate construction to establish parameters for a new vaccine platform that can be applied to new vaccines; 2) We will translate our basic discoveries and use our vaccine platform to make new vaccines against important pathogens such as Francisella tularensis, Burkholderia mallei and pseudomallei, and Brucella abortus. The approach offers a knowledge-based design that will serve as a platform for a wide variety of glycoconjugate vaccines for diseases where vaccines have not been created and to greatly improve current glycoconjugate vaccines.

Public Health Relevance

Markedly improved glycoconjugate vaccines have great potential to deliver safe and very effective immunity to a host of important pathogens. We will develop a platform for making glycoconjugates ofthe highest immunogenicity through rational design based on a new understanding of the mechanisms controlling immune responses to this class of molecules.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109764-03
Application #
9017926
Study Section
Special Emphasis Panel (ZAI1-LR-M)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
$539,366
Indirect Cost
$173,958
Name
Harvard Medical School
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Zhang, Ge; Baidin, Vadim; Pahil, Karanbir S et al. (2018) Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors. Proc Natl Acad Sci U S A 115:6834-6839
Sham, Lok-To; Zheng, Sanduo; Yakhnina, Anastasiya A et al. (2018) Loss of specificity variants of WzxC suggest that substrate recognition is coupled with transporter opening in MOP-family flippases. Mol Microbiol 109:633-641
Lee, Wonsik; Do, Truc; Zhang, Ge et al. (2018) Antibiotic Combinations That Enable One-Step, Targeted Mutagenesis of Chromosomal Genes. ACS Infect Dis 4:1007-1018
Fenton, Andrew K; Manuse, Sylvie; Flores-Kim, Josué et al. (2018) Phosphorylation-dependent activation of the cell wall synthase PBP2a in Streptococcus pneumoniae by MacP. Proc Natl Acad Sci U S A 115:2812-2817
Buss, Jackson A; Baidin, Vadim; Welsh, Michael A et al. (2018) A pathway-directed screen for inhibitors of the bacterial cell elongation machinery. Antimicrob Agents Chemother :
Santiago, Marina; Lee, Wonsik; Fayad, Antoine Abou et al. (2018) Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic. Nat Chem Biol 14:601-608
Baranowski, Catherine; Welsh, Michael A; Sham, Lok-To et al. (2018) Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. Elife 7:
Rohs, Patricia D A; Buss, Jackson; Sim, Sue I et al. (2018) A central role for PBP2 in the activation of peptidoglycan polymerization by the bacterial cell elongation machinery. PLoS Genet 14:e1007726
Vickery, Christopher R; Wood, B McKay; Morris, Heidi G et al. (2018) Reconstitution of Staphylococcus aureus Lipoteichoic Acid Synthase Activity Identifies Congo Red as a Selective Inhibitor. J Am Chem Soc 140:876-879
Bertani, Blake R; Taylor, Rebecca J; Nagy, Emma et al. (2018) A cluster of residues in the lipopolysaccharide exporter that selects substrate variants for transport to the outer membrane. Mol Microbiol 109:541-554

Showing the most recent 10 out of 46 publications